Navigation Links
Insmed CEO Resigns Due to Health Concerns
Date:6/15/2009

l trial data may take longer than anticipated, competing products may be more successful, the biopharmaceutical industry may experience negative market trends, our continuing efforts to grow the business and develop IPLEX(TM) may be unsuccessful, the actual market for MMD may not actually match up with our external assessment, we may lack financial resources to complete development of product candidates and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2008. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

    Investor Relations Contact:
    Brian Ritchie - FD
    212-850-5683
    brian.ritchie@fd.com

    Media Relations Contact:
    Irma Gomez-Dib - FD
    212-850-5761
    irma.gomez-dib@fd.com


'/>"/>
SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Insmed Announces First Quarter 2009 Financial Results
2. Insmed Regains NASDAQ Compliance
3. Insmed to Host First Quarter 2009 Conference Call
4. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
5. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
6. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
7. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
8. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
9. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
10. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
11. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... The ... funds, investment firms and animal health companies to hear from animal health companies ... Several have also received licensing agreements or distribution contracts. This meeting is ...
(Date:8/27/2015)... , Aug. 27, 2015  Neogen Corporation (NASDAQ: ... the stock of United Kingdom -based ... microbiological culture media and diagnostic systems. ... into a leading provider of microbial testing and diagnostic ... testing markets. The company currently sells into more than ...
(Date:8/27/2015)... , Aug. 27, 2015 The ... a patient,s eyes—and life—were saved by doctors at Vanderbilt ... working with NNFF, NovaBay Pharmaceuticals and Dr. John ... Center at Seton Medical Center in ... treatment used a breakthrough approach, pioneered by Dr. Crew, ...
(Date:8/27/2015)... ON , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: ... three and six-month periods ended June 30, 2015. Biorem,s complete second ... www.sedar.com ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ... , 2014 , 2015 , 2014 ... 9,398 , 4,433 Gross profit , 1,656 ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
... , , ... May 11 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ... for the treatment of cancer, today announced the dosing of the ... with SL052 Photodynamic Therapy in prostate cancer patients. The study will ...
... HARBIN, China , May 11 /PRNewswire-Asia-FirstCall/ -- ... Company") (Nasdaq: CSKI ), a leading,fully integrated pharmaceutical company ... ("PRC"), today announced the Company attended,the 107th China Import and ... May 1st,to 5th, 2010 and generated significant interest from ...
... N30 Pharma (N30), a biopharmaceutical company focused on the discovery and development of ... that it has completed a $10 million financing and expanded its Board ... Joining the Company,s Board of Directors ... , , ...
Cached Biology Technology:Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial 2Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial 3China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity 2China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity 3China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity 4
(Date:8/6/2015)... Germany , August 6, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted display ... new solution, unprecedented quality and efficiency is brought to ... displays. For the first time, professionals and researchers can ...
(Date:8/5/2015)... The biosensors market is proving highly attractive ... newer sectors, and development of devices resulting in higher ... seen the entry of multiple participants each year with ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) Recent ... Global Biosensors Market ( http://www.frost.com/nee9 ), finds that ...
(Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... pores ?the all-important channels that control the flow of information ... to prepare for the split to come when a cell ... Institute for Biological Studies watched as new funnel-like pore structures ... , This discovery adds to the picture of how ...
... a protein made by a cancer virus causes infected immune ... to spread. , The virus, the human T lymphotropic ... known as T lymphocytes, or T cells, touch uninfected T ... transmission happens. It suggests that an HTLV-1 protein known as ...
... the lore of marathoners and extreme athletes, lactic acid ... the muscles and leads to muscle fatigue, reduced performance ... the University of California, Berkeley, however, tells a different ... and athletes don't realize it, says exercise physiologist George ...
Cached Biology News:Researchers solve mystery of how nuclear pores duplicate before cell division 2Viral protein helps infected T cells stick to uninfected cells 2Lactic acid not athlete's poison, but an energy source - if you know how to use it 2Lactic acid not athlete's poison, but an energy source - if you know how to use it 3Lactic acid not athlete's poison, but an energy source - if you know how to use it 4
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
... Purpose -- The Varian 1200 ... highest level of flexibility and ... affordable, easy-to-use system. The complete ... guarantees success with today's applications ...
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Biology Products: